Study of BOS161721 in Systemic Lupus Erythematosus (SLE) Patients on a Background of Limited Standard of Care

NCT ID: NCT03371251

Last Updated: 2022-03-14

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 143 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-01-10
• Study Completion Date: 2020-11-26

Brief Summary

This study will be conducted to assess the safety, tolerability, and immunogenicity of repeat doses of BOS161721 (20 milligrams [mg], 60 mg, and 120 mg) administered subcutaneously in adult participants with moderately to severely active Systemic Lupus Erythematosus (SLE) on limited background standard of care treatment, in order to estimate the optimal dose.

BOS161721 at the chosen dose will be compared to placebo for response on the SLE Responder Index 4, with sustained reduction of oral corticosteroids, in the same participant population.

Conditions

Systemic Lupus Erythematosus

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Phase 1b: BOS161721 20, 60, 120 mg

Participants will be randomized to receive a 20 milligram (mg), 60 mg, or 120 mg subcutaneous (SC) dose of BOS161721. Participants may receive a total of 7 SC monthly doses of BOS161721 on Days 0, 30, 60, 90, 120, 150, and 180, followed by safety follow-up visits on at Days 210, 240, and 270.

Group Type: EXPERIMENTAL

BOS161721

Intervention Type: DRUG

SC administration

Phase 1b: Placebo 20, 60, 120 mg

Participants will be randomized to receive a 20 mg, 60 mg, or 120 mg SC dose of placebo. Participants may receive a total of 7 SC monthly doses of placebo on Days 0, 30, 60, 90, 120, 150, and 180, followed by safety follow-up visits on at Days 210, 240, and 270.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

SC administration

Phase 2: BOS161721

Participants will be randomized to receive a 120 mg SC dose of BOS161721 (as determined from Phase 1b of the study). Participants may receive a total of 7 SC monthly doses of BOS161721 on Days 0, 30, 60, 90, 120, 150, and 180, followed by safety follow-up visits on at Days 210, 240, and 270.

Group Type: EXPERIMENTAL

BOS161721

Intervention Type: DRUG

SC administration

Phase 2: Placebo

Participants will be randomized to receive a 120 mg SC dose of placebo (as determined from Phase 1b of the study). Participants may receive a total of 7 SC monthly doses of placebo on Days 0, 30, 60, 90, 120, 150, and 180, followed by safety follow-up visits on at Days 210, 240, and 270.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

SC administration

Interventions

BOS161721

SC administration

Intervention Type: DRUG

Placebo

SC administration

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Men and women, ages 18 to 70 years, inclusive
• Participants must be mentally capable of giving consent and there must be evidence of a personally signed and dated informed consent document indicating that the participant has been informed of all pertinent aspects of the study
• Participants must have Systemic Lupus Erythematosus (SLE) as defined by meeting 4 of the Systemic Lupus International Collaborating Clinics classification criteria for SLE (with at least 1 clinical and 1 immunologic criterion OR Lupus nephritis as the sole clinical criterion in the presence of anti-nuclear antibodies (ANA) or anti-double stranded deoxyribonucleic acid (dsDNA) antibodies), either sequentially or simultaneously
• At screening, participants must have at least 1 of the following:

1. Elevated ANA ≥ 1:80 via immunofluorescent assay at the central laboratory

2. Positive anti-dsDNA or anti-Smith (anti-Sm) above the normal level as determined by the central laboratory

• At screening, the total Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score must be ≥ 8, including points from at least 1 of the following clinical components:

a. Arthritis, rash, myositis, mucosal ulcers, pleurisy, pericarditis, and vasculitis Note: Points from lupus headache and organic brain syndrome will also be excluded from qualifying total and clinical SLEDAI-2K scores at screening and Day 0.

• A clinical SLEDAI-2K score of ≥ 6 at screening at Day 0. Clinical SLEDAI-2K score is defined as follows:

1. Contains points from arthritis, rash, myositis, mucosal ulcers, pleurisy, pericarditis, or vasculitis

2. Excludes parameters which require central laboratory results: hematuria, pyuria, urinary casts, proteinuria, positive anti-dsDNA, decreased complement, thrombocytopenia, and leukopenia Note: Points from lupus headache and organic brain syndrome will also be excluded from qualifying total and clinical SLEDAI-2K scores at screening and Day 0.

• Participants must have at least 1 qualifying A or 2Bs from the following manifestations of SLE, as defined by the British Isles Lupus Assessment Group (BILAG) criteria as modified for use in this study, which must be confirmed by the central data reviewer:

1. BILAG A or B score in the mucocutaneous body system. If a BILAG B score is due to BILAG number 6, mild skin eruption, the CLASI activity score including erythema and scale/hypertrophy must be ≥ 3 excluding points from mucosal ulcers and alopecia.

2. BILAG A or B score in the musculoskeletal body system due to active polyarthritis Note: Hips, shoulders, back, neck, and temporomandibular joints do not count towards the total number of joints with active synovitis.

If only one "B" and no "A" score is present in the mucocutaneous body system or in the musculoskeletal body system due to arthritis, then at least 1 "B" must be present in at least 1 other body system for a total of 2 "B" BILAG body system scores.

• Participants must be currently receiving at least 1 of the following:

1. Administration for a minimum of 12 weeks, and a stable dose for at least 56 days (8 weeks prior to Day 0) of the following permitted steroid sparing agents: azathioprine (AZA), mycophenolate mofetil or mycophenolic acid, chloroquine, hydroxychloroquine, or methotrexate

2. If AZA, myocophenolate mofetil, mycophenolic acid, hydroxychloroquine, or MTX were discontinued prior to screening, the washout period must be ≥ 12 weeks.

3. Corticosteroids (CSs) (prednisone or prednisone-equivalent) at a stable dose of up to 30 mg/day for at least 6 weeks prior to Day 0

i. For participants whose only SLE treatment is CSs, the stable CS dose must be ≥ 10 mg/day for at least 6 weeks prior to Day 0 and no more than 30 mg/day at the time of randomization.

ii. Topical steroids may be used, but the dose must be stable for at least 6 weeks prior to Day 0. PRN topical steroids are not permitted.

• Women of childbearing potential (WOCBP):

1. Must have a negative serum pregnancy test at screening. Urine pregnancy test must be negative prior to first dose

2. Must not be breastfeeding

3. Must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug plus 52 weeks

• Men who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug plus 52 weeks
• Participants must demonstrate willingness and ability to comply with the scheduled study visits, treatment plans, laboratory tests, and other procedures

Exclusion Criteria

Participants presenting with any of the following will not be included in this study:

• Drug-induced SLE, rather than "idiopathic" SLE
• Other systemic autoimmune disease (eg, erosive arthritis, rheumatoid arthritis [RA], multiple sclerosis [MS], systemic sclerosis, or vasculitis not related to SLE). RA-Lupus overlap (Rupus), and secondary Sjogren syndrome are allowed.
• Any major surgery within 6 weeks of study drug administration (Day 0) or any elective surgery planned during the course of the study
• Any history or risk for tuberculosis (TB), specifically those with:

1. Current clinical, radiographic, or laboratory evidence of active TB

2. History of active TB

3. Latent TB defined as positive QuantiFERON-TB Gold In Tube or other diagnostic test in the absence of clinical manifestations. Latent TB is not excluded if the participant has documented completion of adequate course of prophylactic treatment with regimen recommended by local health authority guideline, or the participant has started treatment with isoniazid, or other regimen recommended by local health authority guidelines for at least 1 month before Day 0 and continues to receive the prophylactic treatment during study until the treatment course is completed

• Active or unstable lupus neuropsychiatric manifestations, including but not limited to any condition defined by BILAG A criteria, with the exception of mononeuritis multiplex and polyneuropathy, which are allowed
• Severe proliferative lupus nephritis (World Health Organization Class III, IV), which requires or may require induction treatment with cytotoxic agents or high dose CSs
• Concomitant illness that, in the opinion of the investigator or the Sponsor or their designee, is likely to require additional systemic glucocorticosteroid therapy during the study, (eg, asthma), is exclusionary. However, treatment for asthma with inhalational CSs therapy is allowed.
• Use or planned use of concomitant medication outside of standard of baseline treatment for SLE from Day -1 or for any time during the study
• Active and clinically significant infection (bacterial, fungal, viral, or other) within 60 days prior to first dose of study drug. Clinically significant is defined as requiring systemic parenteral antibiotics or hospitalization
• A history of opportunistic infection, or a history of recurrent or severe disseminated herpes zoster or disseminated herpes simplex within the last 3 years
• Chronic viral hepatitis B (HBV) and hepatitis C (HCV), unless participant received curative treatment for HCV and has a documented negative viral load, known human immunodeficiency virus (HIV), or acquired immunodeficiency syndrome (AIDS)-related illness
• Cryptosporidium in the stool sample at screening
• White blood cells < 1,200/millimeters cubed (mm^3) (1.2 × 10^9/Liter [L]) at screening
• Absolute neutrophil count < 500/mm^3 at screening
• CD4+ count < 150/microliter (µL) at screening
• Platelets < 50,000/mm^3 (50 × 10^9/L) or < 35,000/mm^3 (35 × 10^9/L) if related to SLE, at screening
• Hemoglobin < 8 grams per deciliter (g/dL) or < 7 g/dL at screening if related to SLE
• Proteinuria > 3.0 g/day (3000 milligrams per day [mg/day]) at screening or equivalent level of proteinuria as assessed by protein/creatinine ratio (3 mg/mg or 339 milligrams per millimole [mg/mmol])
• Serum creatinine > 2.0 mg/dL at screening or creatinine clearance < 40 milliliters per minute (mL/minute) based on Cockcroft-Gault calculation
• Serum alanine aminotransferase and/or serum aspartate aminotransferase > 2 × the upper limit of normal (ULN) at screening, unless explicitly related to lupus based on the investigator's judgment
• Creatinine kinase > 3.0 × ULN at screening unless related to lupus myositis
• Total bilirubin > 1.5 × ULN at screening (unless related to Gilbert's syndrome)
• Any other laboratory test results that, in the opinion of the Investigator or the Sponsor or Sponsor's designee, might place a participant at unacceptable risk for participating in this study
• History of allergic or anaphylactic reaction to any therapeutic or diagnostic monoclonal antibodies (mAb) (eg, IgG protein) or molecules made of components of mAbs
• History substance and/or alcohol abuse, or dependence within the past 1 year, at the investigator's judgment
• History of cancer within the last 5 years (except for cutaneous basal cell or squamous cell cancer, or cervical cancer in situ resolved by excision)
• Any other severe acute or chronic medical or psychiatric condition, including recent (within the past year) medical conditions (eg, cardiovascular conditions, respiratory illnesses) that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, Sponsor, or Sponsor's designee, would make the participant inappropriate for entry into this study
• Investigational site staff members directly involved in the conduct of the trial and their family members, site staff members otherwise supervised by the investigator, or participants who are employees of the sponsor or directly involved in the conduct of the trial
• Currently participating in, or who have participated in other interventional (drug or device) clinical study within 30 days or 5 half-lives of baseline, whichever is longer
• Recent (within the past 12 months) or active suicidal ideation or behavior based on participant responding "yes" to question 3, 4, or 5 on the Columbia Suicide severity Rating Scale
• Current or pending incarceration
• Current or pending compulsory detainment for treatment of either a psychiatric or physical (eg, infectious disease) illness
• Currently taking a total daily dose of > 30 mg morphine or morphine equivalent
• Body mass index (BMI) ≥ 40.0

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Boston Pharmaceuticals

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Pinnacle Research Group

Anniston, Alabama, United States

TriWest Research Associates

El Cajon, California, United States

Valerius Medical Group and Research Center

Los Alamitos, California, United States

Westlake Medical Research

Thousand Oaks, California, United States

Clinical Research of West Florida

Clearwater, Florida, United States

Omega Research Consultants

DeBary, Florida, United States

Centre for Rheumatology Immunology and Arthritis

Fort Lauderdale, Florida, United States

Millennium Research

Ormond Beach, Florida, United States

The Arthritis Center

Palm Harbor, Florida, United States

Clinical Research of West Florida

Tampa, Florida, United States

Clinic of Robert Hozman/Clinical Investigation Specialists, Inc.

Skokie, Illinois, United States

Indiana University School of Medicine

Indianapolis, Indiana, United States

Aa Mrc Llc

Grand Blanc, Michigan, United States

June DO PC

Lansing, Michigan, United States

Joint and Muscle Research Institute

Charlotte, North Carolina, United States

Ramesh C. Gupta M.D.

Memphis, Tennessee, United States

Accurate Clinical Research Inc

Houston, Texas, United States

Hospital Militar Central - Servicio de Reumatología

Buenos Aires, , Argentina

Framingham Centro Medico

La Plata, , Argentina

Centro Medico Privado de Reumatologia

San Miguel de Tucumán, , Argentina

Centro de Investigaciones Reumatologicas

San Miguel de Tucumán, , Argentina

Diagnostic Consultative Center Sveti Georgi EOOD

Plovdiv, , Bulgaria

University Multiprofile Hospital for Active Treatment Plovdiv

Plovdiv, , Bulgaria

Medical Center - 1 - Sevlievo EOOD

Sevlievo, , Bulgaria

Centro Integral de Reumatologia del Caribe CIRCARIBE S.A.S

Barranquilla, , Colombia

Preventive Care S.A.S.

Bogotá, , Colombia

Medicity S.A.S.

Bucaramanga, , Colombia

Servimed S.A.S.

Bucaramanga, , Colombia

Clinica de Artritis Temprana

Cali, , Colombia

Hospital Pablo Tobon Uribe

Medellín, , Colombia

V. Tsitlanadze Scientifically-Practical Rheumatology Center Ltd

Tbilisi, , Georgia

Research Institute of Clinical Medicine Ltd

Tbilisi, , Georgia

LTD New Hospitals

Tbilisi, , Georgia

Mtskheta Street Clinic Ltd

Tbilisi, , Georgia

First Medical Center

Tbilisi, , Georgia

Multiprofile Clinic Consilium Medulla Ltd

Tbilisi, , Georgia

Qualiclinic Kft.

Budapest, , Hungary

DE Klinikai Központ

Debrecen, , Hungary

Békés Megyei Központi Kórház Pándy Kálmán Tagkórház

Gyula, , Hungary

Centro Integral en Reumatología S.A. de C.V. (CIRSA)

Guadalajara, , Mexico

Hospital Civil de Guadalajara Fray Antonio Alcalde

Guadalajara, , Mexico

CLIDITER S.A. de C.V. (Centro de Investigación y Tratamiento de las Enfermedades Reumaticas)

Mexico City, , Mexico

Hogar Clinica San Juan De Dios

Cayma, , Peru

Centro de Investigación Clínica Trujillo E.I.R.L.

La Libertad, , Peru

Hospital Nacional Cayetano Heredia

Lima, , Peru

Clinica San Juan Bautista

Lima, , Peru

Instituto de Ginecología y Reproducción

Santiago de Surco, , Peru

Angeles University Foundation Medical Center

Angeles City, , Philippines

Southern Philippines Medical Center

Davao City, , Philippines

Mary Mediatrix Medical Center

Lipa City, , Philippines

Philippine General Hospital

Manila, , Philippines

University of Santo Tomas Hospital

Manila, , Philippines

Centrum Kliniczno - Badawcze J. Brzezicki, B. Gronkiewicz Brzezicka Spółka Lekarska

Elblag, , Poland

Centrum Medyczne Plejady

Krakow, , Poland

Centrum Nowoczesnych Terapii Dobry Lekarz sp. z o.o

Krakow, , Poland

Centrum Medyczne AMED oddział w Łodzi

Lodz, , Poland

NZOZ Lecznica MAK-MED

Nadarzyn, , Poland

Prywatna Praktyka Lekarska Prof. UM dr hab. med Pawel Hrycaj

Poznan, , Poland

SANUS Szpital Specjalistyczny sp. z o.o

Stalowa Wola, , Poland

Reumatika-Centrum Reumatologii

Warsaw, , Poland

Centrul Medical de Diagnostic si Tratament Ambulatoriu Neomed SRL

Brasov, , Romania

Spitalul Clinic Judetean De Urgenta Cluj Napoca

Cluj-Napoca, , Romania

Spitalul Clinic de Recuperare Iasi #2

Iași, , Romania

National Scientific Center at Institute of Cardiology named after acad. M.D. Strazhesko

Kyiv, , Ukraine

Kyiv Regional Clinical Hospital

Kyiv, , Ukraine

Odesa Regional Clinical Hospital

Odesa, , Ukraine

Communal Non-Profit Enterprise "Ternopil University Clinic" of Ternopil Regional Council

Ternopil, , Ukraine

Vinnytsia Regional Clinical Hospital

Vinnytsia, , Ukraine

Countries

United States; Argentina; Bulgaria; Colombia; Georgia; Hungary; Mexico; Peru; Philippines; Poland; Romania; Ukraine

References

Ahmad SB, Jefferson JA. Targeting B Cells and Plasma Cells in Glomerular Disease. J Am Soc Nephrol. 2025 Jun 4;36(9):1844-1857. doi: 10.1681/ASN.0000000772.

Reference Type: DERIVED

PMID: 40465397 (View on PubMed)

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

BOS161721-02

Identifier Type: -

Identifier Source: org_study_id